FDA Approves Merck's SYLATRON for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement

Merck MRK today announced that the U.S. Food and Drug Administration (FDA) has approved SYLATRON for injection, for subcutaneous use. SYLATRON is indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. SYLATRON is contraindicated in patients with a history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b, in patients with autoimmune hepatitis, and in patients with hepatic decompensation.